Amarnath Vedere, MD
Cardiovascular Disease · Wellington, FLNPI 1437141272
Payments from drug & device makers
Across 437 payments — averaging $798.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$151K
- CSL Behring$108K
- Bayer$53K
- Abbott$16K
- E.r. Squibb & Sons, L.L.C.$13K
- Cardiovascular Systems Inc.$2K
- plus $6K from 35 others
Across 1 payment — averaging $9.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$9
What the payments were for
- Speaking & faculty fees$1,50017%
- Food & beverage$7,19883%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 11 | $151,394 |
| CSL Behring | 48 | $107,876 |
| Bayer | 11 | $53,116 |
| Abbott | 24 | $15,833 |
| E.r. Squibb & Sons, L.L.C. | 31 | $12,910 |
| Cardiovascular Systems Inc. | 6 | $1,572 |
| Johnson & Johnson | 108 | $1,052 |
| Bard Peripheral Vascular, Inc. | 36 | $1,042 |
| Novartis | 25 | $457 |
| Boehringer Ingelheim | 18 | $441 |
| Amgen | 23 | $390 |
| Medtronic(2 entities) | 14 | $346 |
| Boston Scientific | 11 | $311 |
| Cvrx, Inc. | 2 | $289 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $222 |
| Philips North America LLC | 3 | $202 |
| Shockwave Medical, Inc | 2 | $196 |
| Cardiva Medical, Inc. | 5 | $147 |
| Kestra Medical Technology Services, Inc. | 3 | $136 |
| Bolton Medical Inc | 2 | $133 |
| Amarin Pharma, Inc. | 6 | $107 |
| AstraZeneca | 6 | $89 |
| Pfizer | 5 | $83 |
| Biotronik Inc. | 1 | $63 |
| Merck | 3 | $62 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $45 |
| Abiomed | 2 | $34 |
| Atricure, Inc. | 1 | $27 |
| Chiesi USA, Inc. | 2 | $27 |
| Kvk-tech, Inc. | 2 | $25 |
| AbbVie | 1 | $21 |
| Cordis US CORP. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Sanofi | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| Edwards Lifesciences | 1 | $16 |
| Cardinal Health 200 LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| G Medical Diagnostic Services, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$348,850 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 280 | $316,978 |
| EntrestoSacubitril/Valsartan | 160 | $204,096 |
| XareltoRivaroxaban | 160 | $166,609 |
| JardianceEmpagliflozin | 64 | $71,736 |
| Repatha SureclickEvolocumab | 65 | $53,949 |
| BrilintaTicagrelor | 54 | $45,930 |
| MultaqDronedarone Hcl | 12 | $12,627 |
| Repatha SyringeEvolocumab | 18 | $10,289 |
| Ranolazine ErRanolazine | 50 | $7,235 |
| Metoprolol Succinate | 321 | $4,916 |
| ClopidogrelClopidogrel Bisulfate | 341 | $3,728 |
| Atorvastatin Calcium | 357 | $3,206 |
| Midodrine Hcl | 22 | $2,215 |
| Losartan Potassium | 212 | $1,711 |
| Nifedipine ErNifedipine | 61 | $1,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $83 | $316,978280 claims |
| NovartisEntresto | $457 | $204,096160 claims |
| Johnson & JohnsonXarelto | $1,052 | $166,609160 claims |
| Boehringer IngelheimJardiance | $441 | $71,73664 claims |
| AstraZenecaBrilinta | $89 | $45,93054 claims |
| Sanofi-aventis U.S. LLCMultaq | $14 | $12,62712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Wellington
- Duccio BaldariWellington$3.5M
- Jean FoucauldWellington$3.5M
- Neerav ShahWellington$2.1M
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.